TITLE

Fat-cat salaries are the best way to get the cream

AUTHOR(S)

Pitcher, George

PUB. DATE

May 2003

SOURCE

Marketing Week (01419285);5/29/2003, Vol. 26 Issue 22, p27

SOURCE TYPE

Trade Publication

DOC. TYPE

Article

ABSTRACT

Focuses on the salary of executives in Great Britain. Increase in the remuneration received by executives in the oil industry as a result of the Iraq conflict; Dissention of the public, especially the press, against the increase in pay received by executives; Issue concerning the proposed pay deal of Jean-Pierre Garnier, chief executive officer of GlaxoSmithKline.

ACCESSION #

9970721

Tags: EXECUTIVE compensation;  PETROLEUM industry;  GARNIER, Jean-Pierre;  GLAXOSMITHKLINE

 

Related Articles

• GSK Revisits Exec Pay. Houlton, Sarah // Pharmaceutical Executive;Feb2004, Vol. 24 Issue 2, p28 

  No abstract available.

• Fat cat cream goes sour.  // European Chemical News;5/26/2003, Vol. 78 Issue 2054, p5 

  Comments on the decision of GlaxoSmithKline (GSK) shareholders to vote down the proposed remuneration package for chief executive officer Jean-Pierre Garnier. Amount of the proposed package; Argument of shareholders against the proposal; Implication of the GSK vote.

• EARNING CURVE: MEDICINE.  // Management Today;May2005, p18 

  The article informs about earning of an executive and other staff in the medicare industry. Jean-Pierre Garnier, CEO of pharmaceutical firm GlaxoSmithKline PLC earns �2.4m per annum. A hospital consultant gets a basic pay of �24.6k-�34.5k p.a.

• Shareholders okay Garnier pay. Beacham, Will // European Chemical News;5/24/2004, Vol. 80 Issue 2101, p9 

  Reports on the approval of the compensation package of Jean-Pierre Garnier, the chief executive officer at GlaxoSmithKline, by shareholders at the British drug group's annual general meeting in May 2004. Value of the compensation package; Potential career changes at the company in 2004 and 2005.

• GKS: A Pipeline to Brag About? Houlton, Sarah // Pharmaceutical Executive;Jan2004, Vol. 24 Issue 1, p22 

  Reports the claim by Jean-Pierre Garnier, chief executive officer of GlaxoSmithKline PLC (GSK), that of the 147 products GSK has in clinical trials, at least 20 have blockbuster potential. Drop in the company's price share; Potential of the company's therapeutic areas; Company's reorganization.

• Gamier Takes the Reigns. Houlton, Sarah // Pharmaceutical Executive;Oct2008, Vol. 28 Issue 10, p22 

  The article reports that Jean-Pierre Garnier, who has resigned from GlaxoSmithKline, is going to France to take his role as general manager of Pierre Fabre Pharmaceuticals Inc. Accordingly, Pierre Fabre Pharmaceuticals Inc., made a turnover of $45 billion in 2007, with its biggest selling...

• GSK Names New Chairman.  // Pharmaceutical Technology;Mar2006, Vol. 30 Issue 3, p174 

  The article announces the appointment of Moncef Slaoui as chairman of research and development at GlaxoSmithKline effective June 1, 2006. Slaoui will report to Chief Executive Officer Jean-Pierre Garnier. Slaoui succeeds Tadataka Yamada who will retire from the company to become executive...

• GSK makes strides in R&D.  // European Chemical News;12/8/2003, Vol. 79 Issue 2080, p28 

  Reports on the research and development (R&D) achievements of GlaxoSmithKline (GSK) presented by chief executive officer Jean-Pierre Garnier to investors in December 2003. Number of projects in clinical development; Number of chemical entities developed by GSK; R&D innovation launched by the...

• JP GARNIER. Davidson, Andrew // Management Today;Mar2004, p38 

  No abstract available.

Read the Article